Post by Sobi - Swedish Orphan Biovitrum AB (publ)

We are proud to share that Sobi maintains the No. 2 position for patient engagement in the PatientView “Corporate Reputation of Pharma Report 2025/2026 - Global Edition” for the second year in a row. * With a growing number of patient stakeholders contributing to the assessment, Sobi was recognised for our continued commitment to patients across areas such as patient centricity, patient safety and integrity. “Being ranked No. 2 again, for two years in row, by the wider patient group audience we work with is a powerful signal of trust. This feedback motivates us to continue learning from the patient community and to further strengthen how we engage and make a difference for the people we serve”, says Giampiero Marra, VP, Head of Global Patient Engagement & Patient Communication at Sobi. PatientView publishes two related but distinct reports each year: a Global Edition, covering all disease areas, and a separate Rare Disease Edition, focusing specifically on companies specialised in rare conditions. The Rare Disease Edition of the report will be published later this year. In the previous Rare Disease Edition (2024/2025), Sobi ranked No. 1 worldwide. Learn more about Sobi’s commitment to patients: https://lnkd.in/dbkhfKYZ   *As rated by patient groups “working with” Sobi. Source: https://lnkd.in/djDTEtmB #Sobi #RareDisease #Unite4Rare #PatientEngagement #Patientview

Video Content